Physicians' Academy for Cardiovascular Education

Bempedoic acid reduces total MACE in high-risk patients with statin intolerance

News - Aug. 27, 2023

Impact of Bempedoic Acid on Total Cardiovascular Events – A Pre-Specified Analysis of the CLEAR Outcomes Study

Presented at the ESC Congress 2023 by:Stephen Nicholls, MD - Melbourne, Australia

Introduction and methods

The CLEAR Outcomes trial recently showed that bempedoic acid reduced first MACE events in high-risk patients with high LDL-c levels who were unwilling or unable to take statins. The current prespecified analysis of the trial assessed the effect of bempedoic acid on total MACE events.

CLEAR Outcomes randomized a total of 13.970 patients to receive either bempedoic acid or placebo for 3.4 years. The primary composite endpoint included CV death, MI, stroke, or coronary revascularization. The key secondary endpoint was the composite of CV death, MI or stroke.

Main results



This prespecified, secondary analysis of the CLEAR Outcomes trial showed that bempedoic acid reduced the total incidence of the composite outcome of CV death, MI, stroke, or coronary revascularization by 20% and the composite of CV death, MI or stroke by 17%. “These findings emphasize the benefits of lowering levels of LDL-C and hsCRP with bempedoic acid in high risk, statin intolerant patients” said Stephen Nicholls.

Share this page with your colleagues and friends: